Advanced search×

[Risperidone use in child and adolescent psychiatric patients].

Therapie 63(5):359-75 (2008) PMID 19154706

In a plural and multidisciplinary process of care, it would be fruitful to ally complementary, pharmacologic and psychodynamic approaches. We have done a review of the literature on the effectiveness and the cautions for prescription of risperidone, a second generation antipsychotic drug. Risperidone has proved helpful in treating children and adolescents with autism spectrum, conduct and bipolar disorders, Tourette's syndrome, and schizophrenia. The principal side effects are sedation, weight gain, and metabolic disturbances. Extrapyramidal symptoms, QTc prolongation, and hyperprolactemia with clinical signs are infrequent and not clinically significant. The benefit/risk is clearly in favor of the prescription when it is accompanied with the precautions and with the adequate monitoring.

DOI: 10.2515/therapie:2008059
Version: za2963e q8zaf q8zbc q8zc5 q8zd1 q8ze9 q8zfe q8zgc

Similar articles you may find interesting…

  1. Risperidone and lamotrigine: no evidence of a drug interaction.

    J Clin Psychiatry 67(7):1159 (2006) PMID 16889467

  2. Cabergoline treatment of risperidone-induced hyperprolactinemia: a pilot study.

    J Clin Psychiatry 65(2):187-90 (2004) PMID 15003071

    Results suggest that low-dose cabergoline treatment of risperidone-induced hyperprolactinemia may be safe and clinically effective in a relevant number of patients....
  3. Risperidone long-acting injection: a prospective 3-year analysis of its use in clinical practice.

    J Clin Psychiatry 70(2):196-200 (2009) PMID 19026261

    The study included 211 evaluable patients. Over 3 years, 84% of subjects discontinued RLAI; 27.7% of these switched to oral risperidone. The Cox model showed that younger age (p = .001), longer duration of illness (p = .001), inpatient status at initiation (p = .002), and an RLAI dose of 25 mg/2 wee...